(Q82723959)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16515768%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Anabolic therapy for osteoporosis: parathyroid hormone (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16515768%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Felicia Cosman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16515768%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16515768%20AND%20SRC:MED&resulttype=core&format=json

Current Rheumatology Reports

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16515768%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16515768%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16515768%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

63-69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16515768%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11926-006-0028-0

17 January 2020

exact match

0 references

cites work

Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women

1 reference

12 December 2020

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

1 reference

12 December 2020

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

1 reference

12 December 2020

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

1 reference

12 December 2020

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

12 December 2020

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

12 December 2020

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

1 reference

12 December 2020

Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy

1 reference

12 December 2020

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

1 reference

12 December 2020

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

12 December 2020

Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size

1 reference

12 December 2020

Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial

1 reference

12 December 2020

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

1 reference

12 December 2020

Daily and cyclic parathyroid hormone in women receiving alendronate

1 reference

12 December 2020

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

12 December 2020

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

1 reference

12 December 2020

Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis.

1 reference

12 December 2020

Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women

1 reference

12 December 2020

Parathyroid hormone and periosteal bone expansion

1 reference

12 December 2020

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study

1 reference

12 December 2020

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

1 reference

12 December 2020

Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis

1 reference

12 December 2020

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

1 reference

12 December 2020

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

12 December 2020

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

1 reference

12 December 2020

Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis

1 reference

12 December 2020

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

1 reference

12 December 2020

Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

1 reference

12 December 2020

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate

1 reference

12 December 2020

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose

1 reference

12 December 2020

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

1 reference

12 December 2020

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020